All In Biotech

Drug Trial Radar · NCT04397562

A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

Last checked: Nov 19, 2026Latest source record: Nov 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

206

Actual

Start

Apr 29, 2020

Primary completion

Jul 3, 2020

Study completion Aug 3, 2020

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
May 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective: to study the efficacy and safety of levilimab in subjects with severe COVID-19.

Conditions

  • COVID-19

Interventions

  • LevilimabDrug

    Levilimab 324 mg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with sustained clinical recoveryTime frame: Day 14

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • State Budgetary Healthcare Institution Kaluga region "Kaluga Regional Clinical Hospital"

    Kaluga, Russia

  • State Budget Institution of the Republic of Dagestan "Republican Clinical Hospital"

    Makhachkala, Russia

  • A.N. Bakulev National Medical Research Center of Cardiovascular Surgery

    Moscow, Russia

  • City Clinical Hospital No. 40 of the Department of Health of the city of Moscow

    Moscow, Russia

  • City Clinical Hospital No.52

    Moscow, Russia

  • City Clinical Hospital № 15 named. O.M. Filatov

    Moscow, Russia

  • City Clinical Hospital №1 named after N.I. Pirogov, Moscow City Health Department

    Moscow, Russia

  • Federal State Budgetary Institution "Central Clinical Hospital with Clinic", Office of the President of the Russian Federation

    Moscow, Russia

  • I.M. Sechenov First Moscow State Medical University (Sechenov University)

    Moscow, Russia

  • Pirogov Russian National Research Medical University

    Moscow, Russia

  • Railway clinical hospital named after N.A. Semashko

    Moscow, Russia

  • Almazov National Medical Research Centre

    Saint Petersburg, Russia

  • Clinical Infectious Disease Hospital named after S.P. Botkin

    Saint Petersburg, Russia

  • North-western State Medical University named after I.I.Mechnikov

    Saint Petersburg, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Healthcare of the Russian Federation

    Ufa, Russia

  • Federal State Budgetary Educational Institution of Higher Education "North Ossetian State Medical Academy" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia)

    Vladikavkaz, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.